protein

Recombinant HTLV-1 Envelope

MBS142595

0.1 mg

225 USD

Recombinant Protein

Recombinant HTLV-1 Envelope

HTLV-1 Envelope

HTLV-1 Envelope; HTLV-1 Envelope Recombinant; HTLV-1 Envelope

Immunoreactive with all sera of HTLV-I and HTLV-II infected individuals with antibody response to HTLV envelope.

HTLV-1 Envelope protein is >95% pure as determined by 10% PAGE (coomassie staining) and RP-HPLC. HTLV-1 Envelope was purified by proprietary chromatographic technique.

10mM Na-PO4 pH 6.0, 0.1% SDS and 1mM DTT. Sterile filtered colorless solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.

VIRAL ANTIGENS- HUMAN T-LYMPHOTROPHIC VIRUS; Viral Antigens; HTLV

Description: The E Coli derived recombinant protein contains the C- terminus of gp46 and most of p21E of HTLV-1. This non-fusion, E Coli-derived protein, starts from HIV-1 env. Amino acid 165, and is ending in amino acid 440, Mw 27 kDa. Introduction: Human T-lymphotropic virus (HTLV) is a human, single-stranded RNA retrovirus that causes T-cell leukemia and T-cell lymphoma. The virus activates a subset of T-helper cellscalled Th1cells. The result is a proliferation of Th1 cells and overproduction of Th1 related cytokines (mainly IFN-gamma and TNF-alpha). Feedback mechanisms of these cytokines cause a suppression of the Th2 lymphocytes and a reduction of Th2 cytokine production (mainly IL-4, IL-5, IL-10 and IL-13). The end result is a reduction in the ability of the infected host to mount an adequate immune response to invading organisms that require a predominantly Th2 dependant response (these include parasitic infections and production of mucosal and humoral antibodies).

0.1 mg

225 USD

0.5 mg

645

1 mg

1030